A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors

被引：0
|
作者：
Rodon, J.
Infante, J.
Burris, H.
Tabernero, J.
Ranson, M. R.
Rouyrre, N.
Duval, V.
Silva, A.
Hackl, W.
Baselga, J.
机构：
[1] Vail Hebron Univ Hosp, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[4] Novartis Pharma AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-15-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-07
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Yan Zhu
    Tiantian Tian
    Jianling Zou
    Qiwei Wang
    Zhongwu Li
    Yanyan Li
    Xijuan Liu
    Bin Dong
    Na Li
    Jing Gao
    Lin Shen
    BMC Cancer, 15
  • [42] The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
    Wu, Yi-Ying
    Wu, Hung-Chang
    Wu, Jia-En
    Huang, Kuo-Yen
    Yang, Shuenn-Chen
    Chen, Si-Xuan
    Tsao, Chao-Jung
    Hsu, Keng-Fu
    Chen, Yuh-Ling
    Hong, Tse-Ming
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [43] The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens
    Yi-Ying Wu
    Hung-Chang Wu
    Jia-En Wu
    Kuo-Yen Huang
    Shuenn-Chen Yang
    Si-Xuan Chen
    Chao-Jung Tsao
    Keng-Fu Hsu
    Yuh-Ling Chen
    Tse-Ming Hong
    Journal of Experimental & Clinical Cancer Research, 38
  • [44] Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer
    Zhu, Yan
    Tian, Tiantian
    Zou, Jianling
    Wang, Qiwei
    Li, Zhongwu
    Li, Yanyan
    Liu, Xijuan
    Dong, Bin
    Li, Na
    Gao, Jing
    Shen, Lin
    BMC CANCER, 2015, 15
  • [45] Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors
    Shapiro, G.
    Kwak, E.
    Baselga, J.
    Rodon, J.
    Scheffold, C.
    Laird, A. D.
    Bedell, C.
    Edelman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] PI3K/mTOR dual inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A synergistically exert anti-tumor activity in breast cancer
    Chen, Liyan
    Jin, Tiefeng
    Zhu, Kun
    Piao, Yingshi
    Quan, Taihao
    Quan, Chunji
    Lin, Zhenhua
    ONCOTARGET, 2017, 8 (07) : 11937 - 11949
  • [47] A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL147, a novel PI3K inhibitor administered orally to patients with advanced solid tumors
    Calvo, E.
    Edelman, G.
    Baselga, J.
    Kwak, E.
    Scheffold, C.
    Nguyen, L.
    Shapiro, G. I.
    EJC SUPPLEMENTS, 2008, 6 (12): : 69 - 69
  • [48] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors (vol 7, pg 704, 2017)
    Baselga, Jose
    CANCER DISCOVERY, 2018, 8 (11) : 1491 - 1491
  • [49] Effects of the Specific PI3K Inhibitor BKM120, the Dual PI3K/mTOR Inhibitor BEZ235, and Specific mTOR Inhibitors Everolimus and Temsirolimus in Renal and Hepatic Carcinoma Models Resistant to Sunitinib and Sorafenib
    Serova, M.
    Raballand, A.
    Dos Santos, C.
    Riveiro, E.
    Raymond, E.
    Faivre, S.
    de Gramont, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 113 - 113
  • [50] Clinical pharmacokinetic-pharmacodynamic (PK/PD) modeling study of the novel dual PI3K/mTOR inhibitor BEZ235.
    Bottino, D.
    Tabernero, J.
    Burris, H. A.
    Britten, C.
    Chen, L. C.
    Bendell, J. C.
    Chiparus, O.
    Duval, V.
    Di Tomaso, E.
    Sarr, C.
    Hackl, W.
    Baselga, J.
    Ahnert, J. Rodon
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345